A Laboratory Model for Heroin Abuse Medications - 8
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heroin Dependence; Opioid-Related Disorders; Substance-Related Disorders
Intervention: opiates (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Herbert Kleber, M.D., Principal Investigator, Affiliation: New York State Psychiatric Institute
Overall contact:
Sandra D Comer, Ph.D., Phone: 212-543-5981, Email: sdc10@columbia.edu
Summary
The purpose of this study is to evaluate the effects of treatment medications (methadone,
buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I. V. and
smoked heroin self-administration."
Clinical Details
Official title: A Laboratory Model for Heroin Abuse Medications
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Placebo Control, Crossover Assignment, Pharmacodynamics Study
Primary outcome: Amount drug self-administered
Secondary outcome: Subjective responses
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
Sandra D Comer, Ph.D., Phone: 212-543-5981, Email: sdc10@columbia.edu
Columbia University, New York, New York 10032, United States; Recruiting
Sandra D Comer, Ph.D., Phone: 212-543-5981, Email: sdc10@columbia.edu
Phillip Saccone, BS, Phone: 212-543-6243, Email: saccone@pi.cpmc.columbia.edu
Additional Information
Starting date: August 1995
Ending date: June 2009
Last updated: October 28, 2008
|
